Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1709

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Dr Reck presents, at a press conference at ESMO 2016, results from the KEYNOTE-024 trial which he believes recommend the use of PD1 antibody pembrolizumab as first-line therapy for patients with NSCLC whose tumours express high levels of PDL-1.

These results complement those presented by Dr Langer, who reports improved outcomes for NSCLC patients receiving firstline pembrolizumab and chemotherapy.

Dr Reck spoke more about these results with ecancer here

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation